Dnf Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.20 M
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth -322.18%
- Ebitda 97.77%
- Net Worth -15.62%
- Total Assets -0.17%
About Dnf Pharmaceuticals India
Dnf Pharmaceuticals India Private Limited (DPIPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 September 2017 (Seven years and four months 25 days old ). Its registered office is in Krishna, Andhra Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Lakshmi Venna and Kodeboyina Jayalakshmi serve as directors at the Company.
Company Details
- Location
Krishna, Andhra Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24290AP2017PTC106770
- Company No.
106770
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Sep 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Who are the key members and board of directors at Dnf Pharmaceuticals India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lakshmi Venna  | Managing Director | 29-Sep-2017 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kodeboyina Jayalakshmi | Director | 29-Sep-2017 | Current |
Financial Performance of Dnf Pharmaceuticals India.
Dnf Pharmaceuticals India Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 322.18% decrease in profit. The company's net worth observed a substantial decline by a decrease of 15.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dnf Pharmaceuticals India?
Unlock access to Dnf Pharmaceuticals India's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dnf Pharmaceuticals India?
Unlock and access historical data on people associated with Dnf Pharmaceuticals India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dnf Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dnf Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.